Anti-trophoblast cell surface antigen 2 targeted drugs: a new targeted therapy for breast cancer

doi:10.3877/cma.j.issn.1674-0785.2022.11.003

Abstract

Abstract:

Breast cancer is a common malignant tumor with significant heterogeneity. After standard treatment, most patients have a good prognosis, but there are still some breast cancer cases with rapid progression and poor prognosis, especially triple negative breast cancer. Therefore, some new treatment strategies are required. Trophoblast cell surface antigen 2 (Trop2) has a high expression rate in breast cancer and may become a potential therapeutic target. At present, there are some developments in drug research and tumor treatment, and some have been approved for clinical application, especially anti-Trop2 antibody–drug conjugate drugs. This article will review the biological function of Trop2 and the latest progress in the anti-Trop-2 targeted treatment of breast cancer.

Key words: Breast neoplasms, Trophoblast cell surface antigen 2, Antibody-drug conjugate

Hong Zhang, Shuang Zhang, Fan Yang. Anti-trophoblast cell surface antigen 2 targeted drugs: a new targeted therapy for breast cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1045-1049.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2022.11.003

https://zhlcyszz.cma-cmc.com.cn/EN/Y2022/V16/I11/1045

References 39

1	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1):7-33.
2	Ensenyat-Mendez M, Llinàs-Arias P, Orozco J, et al. Current triple-negative breast cancer subtypes: dissecting the most aggressive form of breast cancer [J]. Front Oncol, 2021, 11:681476.
3	Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J]. Ann Oncol, 2020, 31(12):1623-1649.
4	Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer [J]. Breast Cancer (Auckl), 2016, 10:25-36.
5	Vidula N, Ellisen LW, Bardia A. Novel agents for metastatic triple-negative breast cancer: finding the positive in the negative [J]. J Natl Compr Canc Netw, 2020:1-9.
6	Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies [J]. Asia Pac J Clin Oncol, 2018, 14(1):32-39.
7	Cubas R, Li M, Chen C, et al. Trop2: a possible therapeutic target for late stage epithelial carcinomas [J]. Biochim Biophys Acta, 2009, 1796(2):309-314.
8	Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target [J]. Oncotarget, 2018, 9(48):28989-29006.
9	Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications [J]. Genes Cancer, 2015, 6(3-4):84-105.
10	Guerra E, Trerotola M, Aloisi AL, et al. The Trop-2 signalling network in cancer growth [J]. Oncogene, 2013, 32(12):1594-1600.
11	Lin H, Zhang H, Wang J, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo [J]. Int J Cancer, 2014, 134(5):1239-1249.
12	Cortesi M, Zanoni M, Maltoni R, et al. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer [J]. Expert Opin Ther Targets, 2022, 26(7):593-602.
13	Zaman S, Jadid H, Denson AC, et al. Targeting Trop-2 in solid tumors: future prospects [J]. Onco Targets Ther, 2019, 12:1781-1790.
14	Zeng P, Chen MB, Zhou LN, et al. Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis [J]. Sci Rep, 2016, 6:33658.
15	Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth [J]. Oncogene, 2013, 32(2):222-233.
16	Gaber A, Kim SJ, Kaake RM, et al. EpCAM homo-oligomerization is not the basis for its role in cell-cell adhesion [J]. Sci Rep, 2018, 8(1):13269.
17	Ripani E, Sacchetti A, Corda D, et al. Human Trop-2 is a tumor-associated calcium signal transducer [J]. Int J Cancer, 1998, 76(5):671-676.
18	Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer [J]. Nucleic Acids Res, 2019, 47(D1):D941-D947.
19	Ambrogi F, Fornili M, Boracchi P, et al. Trop-2 is a determinant of breast cancer survival [J]. PLoS One, 2014, 9(5):e96993.
20	Lenárt S, Lenárt P, Šmarda J, et al. Trop2: Jack of All Trades, Master of None [J]. Cancers (Basel), 2020, 12(11)
21	Liu T, Liu Y, Bao X, et al. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway [J]. PLoS One, 2013, 8(9):e75864.
22	Stoyanova T, Goldstein AS, Cai H, et al. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling [J]. Genes Dev, 2012, 26(20):2271-2285.
23	Aslan M, Hsu EC, Garcia-Marques FJ, et al. Oncogene-mediated metabolic gene signature predicts breast cancer outcome [J]. NPJ Breast Cancer, 2021, 7(1):141.
24	Pak MG, Shin DH, Lee CH, et al. Significance of EpCAM and TROP2 expression in non-small cell lung cancer [J]. World J Surg Oncol, 2012, 10:53.
25	Hsu EC, Rice MA, Bermudez A, et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1 [J]. Proc Natl Acad Sci U S A, 2020, 117(4):2032-2042.
26	Zhao W, Jia L, Kuai X, et al. The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer [J]. Cancer Med, 2019, 8(3):1135-1147.
27	Lipinski M, Parks DR, Rouse RV, et al. Human trophoblast cell-surface antigens defined by monoclonal antibodies [J]. Proc Natl Acad Sci U S A, 1981, 78(8):5147-5150.
28	Remšík J, Binó L, Kahounová Z, et al. Trop-2 plasticity is controlled by epithelial-to-mesenchymal transition [J]. Carcinogenesis, 2018, 39(11):1411-1418.
29	Xie J, Mølck C, Paquet-Fifield S, et al. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells [J]. Oncotarget, 2016, 7(28):44492-44504.
30	Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys [J]. Clin Cancer Res, 2011, 17(10):3157-3169.
31	Goldenberg DM, Cardillo TM, Govindan SV, et al. Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [J]. Oncotarget, 2020, 11(10):942.
32	Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase Ⅰ/Ⅱ IMMU-132-01 basket trial [J]. Ann Oncol, 2021, 32(6):746-756.
33	Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer [J]. N Engl J Med, 2019, 380(8):741-751.
34	Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer [J]. J Clin Oncol, 2022, 40(29):3365-3376.
35	Rugo HS, Bardia A, Marmé F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer [J]. J Clin Oncol, 2022, 40 (suppl 17): abstr LBA1001.
36	Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells [J]. Mol Cancer Ther, 2021, 20(12):2329-2340.
37	Mangino G, Grazia Capri M, Barnaba V, et al. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells [J]. Int J Cancer, 2002, 101(4):353-359.
38	Liu H, Bai L, Huang L, et al. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer [J]. J Immunother Cancer, 2021, 9(10)
39	Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1 [J]. Clin Cancer Res, 2016, 22(20):5097-5108.

[1]	Yaping Jia, Shu'e Zeng. Ultrasound and pathological characteristics of breast metaplastic carcinoma containing squamous cell carcinoma components [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 844-848.
[2]	Wei Tang, Rongquan He, Suning Huang. Application of deep learning in imaging for diagnosis, treatment and prognosis prediction of breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 323-328.
[3]	Xia Kang, Hao Tian, Jin Qian, Yuan Gao, Hongming Miao, Xiaowei Qi. Osteorin attenuates osteolysis during bone metastasis of cancers through inhibiting osteoclastogenesis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 329-339.
[4]	Xiaoli Yi, Shasha Hu, Yan Zhang. Impact of HER-2 low expression on response of neoadjuvant chemotherapy and prognosis in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 340-346.
[5]	Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[6]	Jiaxuan Liu, Binghe Xu. Annual advancement of clinical research on breast cancer in China [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 259-265.
[7]	Chengcai Yao, Changchun Liu, Wenjian Huang, Ming Chen. Single-port non-lipolysis fluorescence-guided laparoscopy for axillary lymph node biopsy in early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 266-271.
[8]	Bohui Shi, Xiping Ding, Lian Wang, Rong Li, Pingli Guo, Jing Qi, Yao Chen, Na Hao, Yu Ren. Summary of best evidences for prevention and treatment of subcutaneous seroma after breast cancer surgery [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 277-284.
[9]	Yaping Wang, Jing Fan, Niuniu Hou, Rui Ling. Clinical significance of tumor-infiltrating lymphocytes in HER-2-positive early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(04): 203-209.
[10]	Wenbo Gao, Ming Li, Yunhao Zhang. Prognostic value and clinical significance of advanced lung cancer inflammation index in patients with triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(04): 210-217.
[11]	Qinqin Zhang, Junnan Wang, Houmin Lin, Ying Wu, Yuemei Tan, Mingzhou Li, Junfei Jin, Ningxia Wang, Yong Hong. Bioinformatics analysis of differential expression and clinical significance of complement 3 in breast cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 271-277.
[12]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[13]	Zhiming Li, Chenming Guo, Xiaochen Zhuang, Xueqin Hou, Junxi Gao. Comparative study of qualitative and quantitative indicators of contrast-enhanced ultrasound in early breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 639-643.
[14]	Hongbo Qu, Fang Zhu, Zhe Xu, Nan Wu, Jianhuai He, Xianming Wang. Application of subclavian lymph node dissection through intermuscular approach in locally advanced breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 510-513.
[15]	Shan Chen, Zhiqiang Hu, Yueming Zhang, Ding Tang, Meng Li, Shuai Zhao. Expression of Orai1 and Orai3 in breast cancer and their correlation with pathological indexes [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 514-517.

Please choose a citation manager

Content to export